Background: The 10-yr survival rate of patients with differentiated thyroid cancer exceeds
90%. These patients may be at elevated risk for secondary cancers. Methods: The risk of …

Context: Increasing incidence and improved prognosis of thyroid cancer have led to concern
about the development of second primary cancers, especially after radioiodine treatment …

Purpose/Objective (s): Approximately 25,000 people are diagnosed with thyroid cancer
annually in the United States, and 90% of them are of the papillary or follicular type. The …

Objective The aim of the present study is to assess the prevalence of second primary tumors
in patients treated for thyroid cancer. Furthermore, we wanted to assess the standardized …

Background: The risk of second primary malignancies (SPMs) associated with cancer
therapies is an important concern of thyroid cancer survivors and physicians. Our objective …

BACKGROUND: Differentiated thyroid cancer survivors are at increased risk of
nonsynchronous second primary malignancy, but the cause remains unclear. This study …

Concerns remain over the risk of cancer following differentiated thyroid carcinoma and its
causes. Iodine-131 (131 I) and external irradiation are known to have potential carcinogenic …

The late health effects associated with radioiodine (131 I) given as treatment for thyroid
cancer are difficult to assess since the number of thyroid cancer patients treated at each …

Abstract BACKGROUND: American Thyroid Association guidelines currently recommend the
selective use of radioactive iodine (RAI) therapy in patients with well differentiated thyroid …

Thyroid cancer incidence rates have increased steadily in the United States and elsewhere.
Radiation exposure at a young age is a strong risk factor, but otherwise the etiology is …